These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33813413)

  • 1. Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy.
    Svaton M; Blazek J; Krakorova G; Pesek M; Buresova M; Teufelova Z; Vodicka J; Hurdalkova K; Barinova M; Topolcan O
    Anticancer Res; 2021 Apr; 41(4):2053-2058. PubMed ID: 33813413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
    Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
    Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CEA, CYFRA21-1 and SCC in non-small cell lung cancer.
    Moro D; Villemain D; Vuillez JP; Delord CA; Brambilla C
    Lung Cancer; 1995 Oct; 13(2):169-76. PubMed ID: 8581396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer.
    Ardizzoni A; Cafferata MA; Tiseo M; Filiberti R; Marroni P; Grossi F; Paganuzzi M
    Cancer; 2006 Dec; 107(12):2842-9. PubMed ID: 17103443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
    Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
    Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
    Chen F; Luo X; Zhang J; Lu Y; Luo R
    Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association of Carcinoembryonic Antigen and Cytokeratin-19 Fragments 21-1 Levels with One-Year Survival of Advanced Non-Small Cell Lung Carcinoma at Cipto Mangunkusumo Hospital: A Retrospective Cohort Study.
    Rumende CM; Sugianto GCK; Rinaldi I; Muhadi M
    Acta Med Indones; 2020 Apr; 52(2):140-146. PubMed ID: 32778628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score.
    Blankenburg F; Hatz R; Nagel D; Ankerst D; Reinmiedl J; Gruber C; Seidel D; Stieber P
    Tumour Biol; 2008; 29(4):272-7. PubMed ID: 18781099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
    Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
    Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information?
    Nisman B; Lafair J; Heching N; Lyass O; Baras M; Peretz T; Barak V
    Cancer; 1998 May; 82(10):1850-9. PubMed ID: 9587116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
    Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
    Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC).
    Muley T; Rolny V; He Y; Wehnl B; Escherich A; Warth A; Stolp C; Schneider MA; Dienemann H; Meister M; Herth FJ; Dayyani F
    Lung Cancer; 2018 Jun; 120():46-53. PubMed ID: 29748014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer.
    Hanagiri T; Sugaya M; Takenaka M; Oka S; Baba T; Shigematsu Y; Nagata Y; Shimokawa H; Uramoto H; Takenoyama M; Yasumoto K; Tanaka F
    Lung Cancer; 2011 Oct; 74(1):112-7. PubMed ID: 21397974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
    Jung M; Kim SH; Hong S; Kang YA; Kim SK; Chang J; Rha SY; Kim JH; Kim DJ; Cho BC
    Yonsei Med J; 2012 Sep; 53(5):931-9. PubMed ID: 22869475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of cytological fluid tumor markers in non-small cell lung cancer.
    Cho A; Hur J; Hong YJ; Lee HJ; Kim YJ; Hong SR; Suh YJ; Im DJ; Kim YJ; Lee JS; Shim HS; Choi BW
    Tumour Biol; 2016 Mar; 37(3):3205-13. PubMed ID: 26432331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
    Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
    J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive and Prognostic Value of CYFRA 21-1 for Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs.
    Takeuchi A; Oguri T; Sone K; Ito K; Kitamura Y; Inoue Y; Asano T; Fukuda S; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Anticancer Res; 2017 Oct; 37(10):5771-5776. PubMed ID: 28982900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
    Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
    J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.